Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pragmatic, prospective study observes the effects of guaraná supplementation on fatigue and quality of life in patients undergoing cancer treatment. Participants take 50 mg of guaraná twice daily for up to six 21-day cycles, with assessments at baseline, week 3, and end of treatment. Primary outcome is change in fatigue using FACIT-F and BFI; secondary outcomes include quality of life (EORTC QLQ-C30), adverse events, and caregiver-perceived quality of life. A subset of 30 participants will have exploratory measurements of inflammatory markers and adherence data collected.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologic diagnosis of breast, lung, colorectal, cervical or gastric cancer
* Receiving active cancer treatment
* Has completed at least three cycles of chemotherapy

Exclusion Criteria:

* Intolerance to the oral route
* Contraindications to guaraná intake
* Uncontrolled cardiovascular disease (uncontrolled atrial fibrillation, symptomatic tachyarrhythmias, prolonged QT)
* History of intolerance to caffeine, methylxanthines, or flavonoids
* Use of CNS stimulants
* Recent history of bleeding
* Use of warfarin or any other vitamin K antagonist
* Use of theophylline

Where it's running

• Fundación CTIC Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
  Bogotá, Bogota D.C., Colombia Recruiting

Study contacts

• Study coordinator: Liliana Gutiérrez, RN, MSc
• Email: lgutierrez@fctic.org
• Phone: +573003768158

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination therapy using checkpoint inhibitors for advanced solid tumors

  This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05187338

• Oral, Fecal and Tumor Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy

  This study tests how the oral, gut, and tumor microbiomes relate to response to first-line immunotherapy in Colombian adults with advanced solid cancers.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07676461

• Timing smartphone messages to boost activity for older cancer survivors with chronic pain

  This study tests whether sending short smartphone messages at certain times can increase physical activity in older cancer survivors with chronic pain.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07227077

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.